Unexplored antifungal activity of linear battacin lipopeptides against planktonic and mature biofilms of C. albicans

Zoysa, Gayan Heruka De; Glossop, Hugh D.; Sarojini, Vijayalekshmi

doi:10.1016/j.ejmech.2018.01.023

Cited by 24 publications

(30 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, BBLP displayed significant antibiofilm activity against M. canis pre-formed biofilm. The results were consistent with the reported activity of battacin lipopeptides against planktonic and mature biofilms of Candida albicans [67]. One important observation during the study was that, BBLP has completely inhibited the growth of M. canis mycelial at a concentration of 1.95 µg/mL while the activity of BBLP was not more than 25.76 % against the M. canis established biofilms in the in vitro microplate assay.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

In Vitro and Ex Vivo Antibiofilm Activity of a Lipopeptide Biosurfactant Produced by the Entomopathogenic Beauveria bassiana Strain against Microsporum canis

et al. 2020

View full text Add to dashboard Cite

Microsporum canis is one of the most important dermatophyte causing tinea corporis and tinea capitis and its biofilm-form has a poor therapeutic response. The biosurfactant production by entomopathogenic fungi (EPF) has not been reported yet. The study aimed to investigate the potential usage of the EPF biosurfactant in the eradication of an ex vivo biofilm of Microsporum canis (M. canis) for the first time. An entomopathogenic fungus was isolated from the fungal-infected Vespa orientalis wasp and identified as Beauveria bassiana (MN173375). Chemical characterization revealed the lipopeptide nature of the B. bassiana biosurfactant (BBLP). Efficient antifungal and antibiofilm activities of BBLP against M. canis in vitro were detected. An ex vivo hair model was used to investigate the efficiency of BBLP against M. canis biofilm, in a scenario close to the in vivo conditions. M. canis ex vivo biofilm eradication was confirmed in stereo, scanning electron, and fluorescent images. Also, the ex vivo biofilm was less susceptible to BBLP treatment compared to its in vitro counterpart. In conclusion, BBLP showed significant eradication to the M. canis ex vivo biofilm and open horizons to use bio-resource derived from EPF in controlling microbial biofilm and holding great promise for combating recalcitrant dermatophytosis.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Many earlier studies revealed that lipopeptide biosurfactants can be a useful approach to challenge microorganisms growing as a biofilm [67][68][69][70]. Dermatophytes grow in the form of a biofilm in vivo, making them difficult to remove surgically and resistant to traditional therapies [50].…”

Section: Discussionmentioning

confidence: 99%

In Vitro and Ex Vivo Antibiofilm Activity of a Lipopeptide Biosurfactant Produced by the Entomopathogenic Beauveria bassiana Strain against Microsporum canis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To determine the effect of morin on eradicating preformed biofilm, C. albicans was allowed to form biofilms in 24-well MTP containing 1 ml of spider broth supplemented with 1% inoculum at 37 • C for 48 h. Then, the planktonic cells were removed and replaced with 1 ml of fresh spider broth supplemented with increasing concentrations of morin (37.5, 75, and 150 µg/ml) and incubated at 37 • C for 16 h. After incubation, the nonadherent cells were washed with sterile PBS and allowed to dry. Then the biofilm biomass was quantified by the crystal violet staining method and visualized by light microscopic analysis (De Zoysa et al, 2018).…”

Section: Eradication Of Mature Biofilm and Light Microscopic Analysismentioning

confidence: 99%

Inhibitory Effect of Morin Against Candida albicans Pathogenicity and Virulence Factor Production: An in vitro and in vivo Approaches

et al. 2020

View full text Add to dashboard Cite

Candida albicans is considered an exclusive etiologic agent of candidiasis, a very common fungal infection in human. The expression of virulence factors contributes highly to the pathogenicity of C. albicans. These factors include biofilm formation, yeast-to-hyphal transition, adhesins, aspartyl proteases, and phospholipases secretion. Moreover, resistance development is a critical issue for the therapeutic failure of antifungal agents against systemic candidiasis. To circumvent resistance development, the present study investigated the virulence targeted therapeutic activity of the phytobioactive compound morin against C. albicans. Morin is a natural compound commonly found in medicinal plants and widely used in the pharmaceutical and cosmetic products/industries. The present study explicated the significant inhibitory potential of morin against biofilm formation and other virulence factors' production, such as yeast-hyphal formation, phospholipase, and exopolymeric substances, in C. albicans. Further, qPCR analysis confirmed the downregulation of biofilm and virlence-related genes in C. albicans upon morin treatment, which is in correspondence with the in vitro bioassays. Further, the docking analysis revealed that morin shows strong affinity with Hwp-1 protein, which regulates the expression of biofilm and hyphal formation in C. albicans and, thereby, abolishes fungal pathogenicity. Moreover, the anti-infective potential of morin against C. albicans-associated systemic candidiasis is confirmed through an in vivo approach using biomedical model organism zebrafish (Danio rerio). The outcomes of the in vivo study demonstrate that the morin treatment effectively rescues animals from C. albicans infections and extends their survival rate by inhibiting the internal colonization of C. albicans. Histopathology analysis revealed extensive candidiasis-related pathognomonic changes in the gills, intestine, and kidney of animals infected with C. albicans, while no extensive abnormalities were observed in morintreated animals. The results evidenced that morin has the ability to protect against the pathognomonic effect and histopathological lesions caused by C. albicans infection in zebrafish. Thus, the present study suggests that the utilization of morin could act as a potent therapeutic medication for C. albicans instigated candidiasis.

show abstract

“…[107] The latter article, and two subsequent publications, examined the potential of octapeptins derived from OctB5 to disrupt and prevent the formation of S. aureus , E. coli and P. aeruginosa biofilms and act as surface coatings,[108] and investigate the antifungal activity of linear analogs. [109] In the last year, four more articles[110–113] have described the first syntheses of other octapeptin family members, initiating a concerted research program to convert them into new antibiotics. Two recent reviews[85, 114] highlight the rapid increase in interest in these compounds and the power of rediscovering compounds from the golden age of antibiotic discovery…”

Section: The Octapeptinsmentioning

confidence: 99%

“…[107] A set of 16 linear analogs, mainly varying the fatty acid substituent, were then prepared for testing their antifungal activity against C. albicans planktonic and biofilm cultures. [109]…”

Section: The Octapeptinsmentioning

confidence: 99%

Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?

Blaskovich

Pitt

Elliott

et al. 2018

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

The octapeptins are a family of cyclic lipopeptides first reported in the 1970s then largely ignored. At the time, their reported antibiotic activity against polymyxin-resistant bacteria was a curiosity. Today, the advent of widespread drug resistance in Gram-negative bacteria has prompted their 'rediscovery.' The paucity of new antibiotics in the clinical pipeline is coupled with a global spread of increasing antibiotic resistance, particularly to meropenem and polymyxins B and E (colistin). Areas covered: We review the original discovery of octapeptins, their recent first chemical syntheses, and their mode of action, then discuss their potential as a new class of antibiotics to treat extensively drug-resistant (XDR) Gram-negative infections, with direct comparisons to the closely related polymyxins. Expert commentary: Cyclic lipopeptides in clinical use (polymyxin antibiotics) have significant dose-limiting nephrotoxicity inherent to their chemotype. This toxicity has prevented improved polymyxin analogs from progressing to the clinic, and tainted the perception of lipopeptide antibiotics in general. We argue that the octapeptins are fundamentally different from the polymyxins, with a disparate mode of action, spectra of action against MDR and XDR bacteria and a superior preclinical safety profile. They represent early-stage candidates that can help prime the antibiotic discovery pipeline.

show abstract

Unexplored antifungal activity of linear battacin lipopeptides against planktonic and mature biofilms of C. albicans

Cited by 24 publications

References 53 publications

In Vitro and Ex Vivo Antibiofilm Activity of a Lipopeptide Biosurfactant Produced by the Entomopathogenic Beauveria bassiana Strain against Microsporum canis

In Vitro and Ex Vivo Antibiofilm Activity of a Lipopeptide Biosurfactant Produced by the Entomopathogenic Beauveria bassiana Strain against Microsporum canis

Inhibitory Effect of Morin Against Candida albicans Pathogenicity and Virulence Factor Production: An in vitro and in vivo Approaches

Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?

Contact Info

Product

Resources

About